Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
MENLO PARK, Calif., Jan. 22, 2016 -- Pacific Biosciences of California, Inc. (Nasdaq:PACB) is announcing a date change for its conference call to report 4th Quarter and Fiscal Year 2015 financial results. The call with now occur on Wednesday, February 3, at 4:30pm Eastern Time.
The call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/.
Date: February 3, 2016
Time: 4:30pm ET
Listen via Internet: http://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Replay: http://investor.pacificbiosciences.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Pacific Biosciences' technology provides the industry's highest consensus accuracy over the longest read lengths in combination with the ability to detect real-time kinetic information. PacBio sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Contact: Pacific Biosciences Trevin Rard 650.521.8450 [email protected]
